English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, August 22, 2022
Sirnaomics獲納入恒生指數系列成份股
Sirnaomics Becoming A Constituent of Hang Seng Family of Indexes
Friday, August 19, 2022
Sirnaomics核心产品RNAi治疗药物STP705用于治疗面部原位鳞状细胞皮肤癌的I/II期临床试验完成首例受试者给药
Sirnaomics核心產品RNAi治療藥物STP705用於治療面部原位鱗狀細胞皮膚癌的I/II期臨床試驗完成首例受試者給藥
Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
Tuesday, August 16, 2022
Sirnaomics研发用于优化GalNAc递送平台的肽对接载体(PDoV(TM)),致力于创新siRNA疗法
Sirnaomics研發用於優化GalNAc遞送平台的肽對接載體(PDoV(TM)),致力於創新siRNA療法
Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
Tuesday, July 26, 2022
Sirnaomics RNAi候选药物STP705用于治疗肝癌的I期临床研究IND申请已获台湾卫生福利部批准
Sirnaomics RNAi候選藥物STP705用於治療肝癌的I期臨床研究IND申請已獲台灣衛生福利部批准

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575